Thomas Jens Scriba

Title: Thomas Jens Scriba: Innovator in Tuberculosis Research

Introduction

Thomas Jens Scriba is a notable inventor based in Cape Town, South Africa. He has made significant contributions to the field of tuberculosis research, particularly in the development of methods for predicting the progression of latent tuberculosis to active disease. With two patents to his name, Scriba's work is pivotal in enhancing the understanding and management of tuberculosis.

Latest Patents

Scriba's latest patents include a method for predicting progression to active tuberculosis disease. This invention provides a gene signature that helps determine the likelihood of a latent tuberculosis infection transitioning to active TB disease. The gene signature comprises at least SEPT4 and BLK, with optional inclusion of GAS6 and/or CD1C. The expression levels of these genes are detected in a sample from the subject, and the ratios of expression of at least two of the genes are calculated. A score is assigned to each ratio, indicating the likelihood of the latent TB infection transitioning into active TB disease.

Another significant patent involves biomarkers for prospective determination of risk for the development of active tuberculosis. This invention relates to a prognostic method for assessing the risk of an asymptomatic human subject with latent tuberculosis infection progressing to active tuberculosis disease. The method includes quantifying and computationally analyzing the relative abundances of pairs of gene products derived from a sample obtained from the subject. Additionally, a kit comprising gene-specific primers or oligonucleotide probes for the detection of these TB biomarkers is described.

Career Highlights

Throughout his career, Thomas Jens Scriba has worked with esteemed institutions such as the University of Cape Town and Seattle Children's Hospital. His research has focused on innovative approaches to understanding and combating tuberculosis, making him a key figure in this critical area of public health.

Collaborations

Scriba has collaborated with notable colleagues, including Ethan Greene Thompson and Daniel Edward Zak. These partnerships have contributed to the advancement of his research and the development of his patents.

Conclusion

Thomas Jens Scriba's contributions to tuberculosis research through his innovative patents highlight his commitment to improving public health. His work not only enhances the understanding of latent tuberculosis but also provides valuable tools for predicting and managing the disease.